If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns
CJC1295 5mg / Ipamorelin 5mg a pair of growth hormonereleasing peptides that support recovery, lean body mass, and restorative sleep by nudging your bodys own growth hormone signaling
For international travel, you may need to visit a local clinic
The FDA has issued warnings about compounded semaglutide products sold without prescriptions or from unlicensed sources, noting reports of adverse events associated with products of uncertain purity and potency [7]
[1] It is important to understand that FDA-approved tirzepatide is supplied as a pre-filled, single-dose pen containing a sterile solution ready for injection
.png)
